Cochlear faces China competition
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Cochlear Ltd's strength in the Chinese market is under threat as Chinese bionic ear maker Nurotron Biotechnology has received approval allowing it to compete with Cochlear for lucrative Chinese government contracts, according to The Australian Financial Review.
Nurotron has been granted approval to provide implants to children, allowing it to participate in the Chinese government's five-year program, which launched last year, to provide underprivileged children with hearing implants.
Nurotron also said it plans over the next four years to build a new factory that will be 10 times the size of its existing facility.
The first test for both firms will come via a key government tender in August.
“We think we have a good chance of winning because the government likes to support Chinese technology and Chinese companies,” Nurotron chairman Li Fangping told the AFR.
“This is good news for poor families across China because we can offer good quality products at competitive prices.”